<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00501982</url>
  </required_header>
  <id_info>
    <org_study_id>DM/PR/5000/002/04</org_study_id>
    <nct_id>NCT00501982</nct_id>
  </id_info>
  <brief_title>Efficacy of Combining Prophylactic Curosurf With Early Nasal CPAP in Delivery Room: the Curpap Study</brief_title>
  <acronym>Curpap</acronym>
  <official_title>An International, Open, Randomized, Controlled Study to Evaluate the Efficacy of Combining Prophylactic Curosurf® With Early Nasal CPAP Versus Early Nasal CPAP Alone in Very Preterm Infants at Risk of Respiratory Distress Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chiesi Farmaceutici S.p.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chiesi Farmaceutici S.p.A.</source>
  <brief_summary>
    <textblock>
      The primary objective of this study is to compare two methods of post-delivery stabilization&#xD;
      and subsequent early respiratory care for reducing the need for MV and related secondary&#xD;
      complications, such as BPD, in premature babies at high risk of RDS:&#xD;
&#xD;
        1. Early stabilization on nCPAP&#xD;
&#xD;
        2. Intubation, prophylactic surfactant (Curosurf®) administration shortly after delivery,&#xD;
           and rapid extubation to nCPAP.&#xD;
&#xD;
      The data obtained from this comparison will be applied to test the hypothesis that preterm&#xD;
      neonates at risk of RDS who are treated with prophylactic surfactant + nCPAP show less need&#xD;
      for MV when compared to infants who receive nCPAP alone.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2007</start_date>
  <completion_date type="Actual">May 2008</completion_date>
  <primary_completion_date type="Actual">May 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Need for MV</measure>
    <time_frame>Within the first 5 days of life</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of BPD and other complications of prematurity. Lenght of hospitalization. Clinical status until discharge home</measure>
    <time_frame>entire study</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">208</enrollment>
  <condition>Respiratory Distress Syndrome, Newborn</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>N Cpap in delivery room and than rescue curosurf in case of need</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Poractant alfa (Curosurf) + N Cpap in delivery room</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Poractant alfa (Curosurf®)</intervention_name>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Preterm neonates with a gestational age (GA) of 25+0 - 28+6 completed weeks.&#xD;
&#xD;
          -  Inborn neonates.&#xD;
&#xD;
          -  In case of twins, both neonates will be included in the same treatment arm.&#xD;
&#xD;
          -  Parental written informed consent for participation in the study obtained on admission&#xD;
             into the hospital or prior to delivery.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Evidence of severe birth asphyxia, that is an APGAR score below 3 at 5 minutes of age.&#xD;
&#xD;
          -  Need for endotracheal intubation for cardiopulmonary resuscitation or insufficient&#xD;
             respiratory drive.&#xD;
&#xD;
          -  Known genetic or chromosomal disorders.&#xD;
&#xD;
          -  Delivered to mothers with ruptured membranes of more than 3 weeks duration.&#xD;
&#xD;
          -  Potentially life-threatening conditions unrelated to immaturity.&#xD;
&#xD;
          -  Participation in another clinical trial of any placebo, drug, biological, or device&#xD;
             conducted under the provisions of a protocol.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Weeks</minimum_age>
    <maximum_age>28 Weeks</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Laura Fabbri</last_name>
    <role>Study Director</role>
    <affiliation>Medical Department; Chiesi Farmaceutici S.p.A (Italy)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>General Faculty Hospital</name>
      <address>
        <city>Prague</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital De La Conception</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Maggiore</name>
      <address>
        <city>Bologna</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maternidade Alfredo da Costa</name>
      <address>
        <city>Lisbon</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital De Cruces</name>
      <address>
        <city>Bilbao</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Czechia</country>
    <country>France</country>
    <country>Italy</country>
    <country>Portugal</country>
    <country>Spain</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
  </removed_countries>
  <link>
    <url>https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004105-25</url>
    <description>Study Record on EU Clinical Trials Register including results</description>
  </link>
  <results_reference>
    <citation>Sandri F, Plavka R, Ancora G, Simeoni U, Stranak Z, Martinelli S, Mosca F, Nona J, Thomson M, Verder H, Fabbri L, Halliday H; CURPAP Study Group. Prophylactic or early selective surfactant combined with nCPAP in very preterm infants. Pediatrics. 2010 Jun;125(6):e1402-9. doi: 10.1542/peds.2009-2131. Epub 2010 May 3.</citation>
    <PMID>20439601</PMID>
  </results_reference>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 16, 2007</study_first_submitted>
  <study_first_submitted_qc>July 16, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 17, 2007</study_first_posted>
  <last_update_submitted>July 30, 2020</last_update_submitted>
  <last_update_submitted_qc>July 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>surfactant</keyword>
  <keyword>RDS</keyword>
  <keyword>nCPAP</keyword>
  <keyword>Mechanical Ventilation</keyword>
  <keyword>Premature Infants</keyword>
  <keyword>Neonatal Respiratory Distress Syndrome (nRDS)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Distress Syndrome</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Newborn</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Poractant alfa</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

